세계의 의약품 시장 예측(-2030년) : 제품 유형별, 투여 경로별, 치료 영역별, 최종사용자별, 지역별 분석

According to Stratistics MRC, the Global Pharmaceuticals Market is accounted for $1.6 billion in 2024 and is expected to reach $2.6 billion by 2030 growing at a CAGR of 8.4% during the forecast period. Pharmaceuticals are drugs and medications developed for use in medical diagnosis, treatment, prevention, and alleviation of diseases. This field encompasses the entire process from the discovery of new compounds to their development, testing, regulatory approval, production, and distribution. Pharmaceuticals include a wide range of products, from over-the-counter drugs to prescription medications, vaccines, and biologics. The industry is highly regulated to ensure drug safety, efficacy, and quality, requiring extensive research, clinical trials, and adherence to standards set by authorities like the FDA. Pharmaceuticals play a critical role in modern healthcare, enabling the management of various health conditions, enhancing patient outcomes, and contributing to public health.

Market Dynamics:

Driver:

Increasing incidence of chronic diseases increases

Increasing incidence of chronic diseases drives demand for ongoing medication, specialized treatments, and innovative therapies, leading to higher sales and revenue growth for pharmaceutical companies. This trend also stimulates research and development investments, fostering the creation of new and improved drugs. Additionally, it encourages partnerships and collaborations within the industry to address complex health challenges propelling the markets growth.

Restraint:

Public scrutiny of high drug prices

Public scrutiny can lead to increased regulatory pressure and legislative actions aimed at controlling or reducing drug prices. It may also result in reputational damage, affecting stock prices and investor confidence. Companies might face reduced profit margins, hampering their ability to invest in research and development for new drugs hampering its growth during the forecast period.

Opportunity:

Increased government spending on healthcare

Increased government nvestment enhances healthcare infrastructure and supports broader distribution of essential drugs, driving higher demand and sales for pharmaceutical companies. It also funds research and development initiatives, fostering innovation and the introduction of new therapies. Moreover, government spending often includes subsidies and reimbursement programs, making medications more affordable for patients encouraging growth of the market.

Threat:

Generic competition

Patents for branded drugs expire, generic drug makers can produce and sell cheaper versions of these medications, leading to a sharp decline in the sales of the original products. This increased availability of lower-cost alternatives drives down prices across the market, reducing profit margins for both brand-name and generic pharmaceutical companies thereby the presence of generics also forces branded drug manufacturers to invest more in marketing and innovation to differentiate their products, increasing operational costs.

Covid-19 Impact:

The COVID-19 pandemic profoundly impacted the pharmaceuticals market, accelerating innovation and the development of vaccines and treatments. It increased demand for medications, diagnostics, and healthcare supplies, boosting revenues for many companies. However, it also disrupted supply chains, delayed clinical trials, and strained resources. The crisis emphasized the importance of agility and collaboration in the industry, leading to rapid advancements and a renewed focus on global health preparedness and resilience against future pandemics.

The branded drugs segment is expected to be the largest during the forecast period

The branded drugs is expected to be the largest during the forecast period because these drugs, protected by patents, allow pharmaceutical companies to recoup research and development costs and fund further innovation. They often command higher prices, contributing to substantial revenue and profitability for their manufacturers and branded drugs remain crucial for advancing medical treatments and addressing unmet healthcare needs.

The oncology segment is expected to have the highest CAGR during the forecast period

The oncology segment is expected to have the highest CAGR during the forecast period owing to the high prevalence of cancer worldwide creates substantial demand for effective treatments, positioning oncology as a top priority for pharmaceutical companies. This focus leads to the development of innovative therapies, including targeted treatments, immunotherapy's, and personalized medicine, which command high prices and generate substantial revenue ensuring sustained growth and innovation within the industry.

Region with largest share:

North America is projected to hold the largest market share during the forecast period North America, particularly the U.S., represents a significant portion of the global pharmaceuticals market. The market is characterized by strong growth due to aging populations, increasing prevalence of chronic diseases, and high demand for innovative treatments. Further the region is a leader in pharmaceutical innovation, with substantial investments in research and development.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period as the Asia-Pacific region is experiencing significant growth due to increasing healthcare needs, rising disposable incomes, and expanding access to healthcare services. Countries like China and India are major contributors to this growth, with their large populations and improving healthcare infrastructure. Local companies are major players in the generic drug market, contributing to the region's growing pharmaceutical industry.

Key players in the market

Some of the key players in Pharmaceuticals market include Pfizer Inc., Johnson & Johnson, Roche Holding AG, Novartis International AG, Merck & Co., Inc. (MSD), Bristol-Myers Squibb, Sanofi, GlaxoSmithKline, AstraZeneca, AbbVie Inc., Eli Lilly and Company, Bayer AG, Amgen Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Gilead Sciences, Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc. and Biogen Inc.

Key Developments:

In July 2024, Johnson & Johnson strengthened pipeline to lead in atopic dermatitis with acquisition of Yellow Jersey Therapeutics. The company is leveraging a multi-pathway approach to transform treatment in atopic dermatitis and other immune-mediated diseases

In June 2024, Pfizer Inc. and BioNTech received positive CHMP opinion for Omicron JN.1-adapted COVID-19 vaccine in the European Union. The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older

In June 2024, Bayer receives breakthrough therapy designation in China for BAY 2927088 in high unmet need patients with HER2-mutant non-small cell lung cancer. The Center for Drug Evaluation in China has granted breakthrough therapy designation to expedite the development

Product Types Covered:

• Branded Drugs
• Generic Drugs
• OTC (Over-the-Counter) Drugs
• Biopharmaceuticals
• Vaccines
• Other Product Types

Route of administrations Covered:

• Oral
• Injectable
• Topical
• Inhalation
• Transdermal
• Nasal
• Other Route of administrations

Therapy Areas Covered:

• Oncology
• Cardiovascular Diseases
• Neurology
• Respiratory Diseases
• Gastrointestinal Disorders
• Infectious Diseases
• Diabetes
• Other Therapy Areas

End Users Covered:

• Clinics
• Hospitals
• Home Care Settings
• Research & Academic Institutes
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Pharmaceuticals Market, By Product Type

• 5.1 Introduction
• 5.2 Branded Drugs
• 5.3 Generic Drugs
• 5.4 OTC (Over-the-Counter) Drugs
• 5.5 Biopharmaceuticals
• 5.6 Vaccines
• 5.7 Other Product Types

6 Global Pharmaceuticals Market, By Route of administration

• 6.1 Introduction
• 6.2 Oral
  • 6.2.1 Tablets
  • 6.2.2 Capsules
  • 6.2.3 Liquids
  • 6.2.4 Syrups
• 6.3 Injectable
  • 6.3.1 Intravenous
  • 6.3.2 Intramuscular
  • 6.3.3 Subcutaneous
  • 6.3.4 Infusions
• 6.4 Topical
  • 6.4.1 Creams
  • 6.4.2 Ointments
  • 6.4.3 Gels
  • 6.4.4 Patches
• 6.5 Inhalation
  • 6.5.1 Metered-Dose Inhalers
  • 6.5.2 Dry Powder Inhalers
  • 6.5.3 Nebulizers
• 6.6 Transdermal
• 6.7 Nasal
• 6.8 Other Route of administrations

7 Global Pharmaceuticals Market, By Therapy Area

• 7.1 Introduction
• 7.2 Oncology
• 7.3 Cardiovascular Diseases
• 7.4 Neurology
• 7.5 Respiratory Diseases
• 7.6 Gastrointestinal Disorders
• 7.7 Infectious Diseases
• 7.8 Diabetes
• 7.9 Other Therapy Areas

8 Global Pharmaceuticals Market, By End User

• 8.1 Introduction
• 8.2 Clinics
• 8.3 Hospitals
• 8.4 Home Care Settings
• 8.5 Research & Academic Institutes
• 8.6 Other End Users

9 Global Pharmaceuticals Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Pfizer Inc.
• 11.2 Johnson & Johnson
• 11.3 Roche Holding AG
• 11.4 Novartis International AG
• 11.5 Merck & Co., Inc. (MSD)
• 11.6 Bristol-Myers Squibb
• 11.7 Sanofi
• 11.8 GlaxoSmithKline
• 11.9 AstraZeneca
• 11.10 AbbVie Inc.
• 11.11 Eli Lilly and Company
• 11.12 Bayer AG
• 11.13 Amgen Inc.
• 11.14 Takeda Pharmaceutical Company Limited
• 11.15 Boehringer Ingelheim
• 11.16 Gilead Sciences, Inc.
• 11.17 Novo Nordisk A/S
• 11.18 Teva Pharmaceutical Industries Ltd.
• 11.19 Astellas Pharma Inc.
• 11.20 Biogen Inc.